AI Analysis
AI-generated analysis. Always verify with the original filing.
Kazia Therapeutics released its March 2026 corporate overview and fact sheet, highlighting paxalisib clinical progress in TNBC and GBM, NDL2 development toward IND in 2026, and US$46 million cash runway into 2029.
Key Takeaways
1Cash and equivalents approximately US$46 million, runway into 2029 excluding additional trials, no outstanding debt.
2Paxalisib: complete metabolic response in stage IV TNBC expanded access patient, two partial responses in ongoing Phase 1b metastatic TNBC study.
3GBM AGILE Phase 2/3 trial showed clinically meaningful OS improvement in newly diagnosed unmethylated GBM patients.
4NDL2 PD-L1 protein degrader: IND initiating studies commencing 2026.
5American Depository Shares outstanding: approximately 11.4 million.
6Upcoming catalysts include FDA discussion on paxalisib GBM path Q2 2026 and breast cancer study readouts 2H 2026.